COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04345614

Sudarshan Hebbar, MD

sudarshan@calcimedica.com

2020-04-14

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any specimen, as documented by either of the following: pcr positive in sample collected < 72 hours prior to randomization; pcr positive in sample collected ≥ 72 hours prior to randomization, with inability to obtain a repeat sample (e.g. due to lack of testing supplies, or limited testing capacity, or results taking >24 hours, etc.) or progressive disease suggestive of ongoing sars-cov-2 infection; at least 1 of the following symptoms: fever, cough, sore throat, malaise, headache, muscle pain, dyspnea at rest or with exertion, confusion, or respiratory distress; at least 1 of the following signs at screening or noted in the 24 hours before screening: pao2/fio2 ≤200 when receiving supplemental oxygen. the pao2/fio2 may be estimated from pulse oximetry (appendix 1) or determined by arterial blood gas; if spo2 ≥97%, must be receiving 10l or more of supplemental oxygen; the presence of a respiratory infiltrate or abnormality consistent with pneumonia that is documented by either a chest x-ray or computerized tomography scan of the lungs; the patient is ≥ 18 years of age; a female patient of childbearing potential must not attempt to become pregnant for 39 months, and if sexually active with a male partner, is willing to practice acceptable methods of birth control for 39 months after the last dose of cm4620-ie; a male patient who is sexually active with a female partner of childbearing potential is willing to practice acceptable methods of birth control for 39 months after the last dose of cm4620-ie. a male patient must not donate sperm for 39 months; the patient is willing and able to, or has a legal authorized representative (lar) who is willing and able to, provide informed consent to participate, and to cooperate with all aspects of the protocol.

expected survival or time to withdrawal of life-sustaining treatments expected to be <7 days. do not intubate order; home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing; pao2/fio2 ≤75 at the time of screening. the pao2/fio2 may be estimated from pulse oximetry (appendix 1) or determined by arterial blood gas; noninvasive positive pressure ventilation; invasive mechanical ventilation via endotracheal intubation or tracheostomy; extracorporeal membrane oxygenation (ecmo); shock defined by the use of vasopressors; multiple organ dysfunction or failure; positive influenza a or b testing if tested as local standard of care; the patient has a history of: organ or hematologic transplant; hiv; active hepatitis b, or hepatitis c infection; current treatment with: chemotherapy; immunosuppressive medications or immunotherapy (section 5.3 for list of prohibited immunosuppressive medications and immunotherapy) at the time of consent; hemodialysis or peritoneal dialysis; have a history of venous thromboembolism (vte) (deep vein thrombosis [dvt] or pulmonary embolism [pe]) within 12 weeks prior to screening or have a history of recurrent (> 1) vte; the patient is known to be pregnant or is nursing; currently participating in another study of an investigational drug or therapeutic medical device at the time of consent; allergy to eggs or any of the excipients in study drug.

2

CalciMedica, Inc.

18

None

United States

Severe disease at enrollment

6: Severe disease at enrollment

284

Number of days from the Start of the First Infusion of Study Drug (SFISD) to recovery

None

Phase 2

[{"arm_notes": "", "treatment_id": 151, "treatment_name": "Auxora", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]